MX2019014674A - Virus recombinante de sarampion que expresa proteinas de virus zika y sus aplicaciones. - Google Patents

Virus recombinante de sarampion que expresa proteinas de virus zika y sus aplicaciones.

Info

Publication number
MX2019014674A
MX2019014674A MX2019014674A MX2019014674A MX2019014674A MX 2019014674 A MX2019014674 A MX 2019014674A MX 2019014674 A MX2019014674 A MX 2019014674A MX 2019014674 A MX2019014674 A MX 2019014674A MX 2019014674 A MX2019014674 A MX 2019014674A
Authority
MX
Mexico
Prior art keywords
zikv
virus
present
proteins
recombinant
Prior art date
Application number
MX2019014674A
Other languages
English (en)
Inventor
Frédéric Tangy
Etienne Simon-Loriere
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of MX2019014674A publication Critical patent/MX2019014674A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18423—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
    • G01N2333/12—Mumps virus; Measles virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a proteínas de virus Zika que expresan el virus recombinante de sarampión y sus aplicaciones, en particular en inducir protección preventiva contra el virus Zika. La presente invención se dirige a virus recombinante de sarampión (MV) que expresa al menos (i) el precursor de la proteína de membrana (prM) de un virus Zika (ZIKV), y la proteína de envoltura (E) de un ZIKV o una versión truncada del mismo, o (ii) la proteína E de un ZIKV o una versión truncada del mismo, y se refiere a partículas infecciosas recombinantes del MV-ZIKV capaz de replicarse en un hospedero después de una administración, y también Partículas Similares a Virus (VLP) que contienen estas proteínas ZIKV en su superficie. La presente invención proporciona medios, en particular ácidos nucleicos, vectores, células y sistemas de rescate para producir estas partículas infecciosas recombinantes y VLPs. La presente invención también se refiere al uso de estas partículas infecciosas recombinantes y/o VLP, en particular bajo la forma de una composición, de manera más particular en una formulación de vacuna, para la prevención de una infección por ZIKV o para la protección preventiva contra resultados clínicos de la infección por ZIKV.
MX2019014674A 2017-06-07 2018-06-06 Virus recombinante de sarampion que expresa proteinas de virus zika y sus aplicaciones. MX2019014674A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305676.3A EP3412307A1 (en) 2017-06-07 2017-06-07 Recombinant measles virus expressing zika virus proteins and their applications
PCT/EP2018/064943 WO2018224573A1 (en) 2017-06-07 2018-06-06 Recombinant measles virus expressing zika virus proteins and their applications

Publications (1)

Publication Number Publication Date
MX2019014674A true MX2019014674A (es) 2020-09-07

Family

ID=59276634

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014674A MX2019014674A (es) 2017-06-07 2018-06-06 Virus recombinante de sarampion que expresa proteinas de virus zika y sus aplicaciones.

Country Status (9)

Country Link
US (1) US11857616B2 (es)
EP (2) EP3412307A1 (es)
JP (2) JP2020524496A (es)
CN (1) CN110891600B (es)
AU (1) AU2018281889B2 (es)
BR (1) BR112019025310A2 (es)
CA (1) CA3064322A1 (es)
MX (1) MX2019014674A (es)
WO (1) WO2018224573A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3031923A1 (en) * 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
KR101966841B1 (ko) * 2018-12-12 2019-04-08 대한민국 지카바이러스 e 단백질 유래의 재조합 항원 및 이의 용도
MX2021012424A (es) * 2019-04-10 2022-02-10 Univ Leuven Kath Virus quimérico de zika-encefalitis japonesa.
CN113999823B (zh) * 2021-12-30 2022-04-26 北京赛尔富森生物科技有限公司 D8基因型嵌合麻疹病毒减毒株和制备方法及用途
WO2023164441A1 (en) * 2022-02-22 2023-08-31 Vyro Bio Inc. Nucleic acid compositions for delivering exogenous polynucleotides and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2110382A1 (en) 2002-06-20 2009-10-21 Institut Pasteur Infectious cDNA of an improved vaccine strain of measles virus, use for immunogenic compositions
ES2423518T3 (es) 2006-12-22 2013-09-20 Institut Pasteur Células y metodología para generar virus de ARN de cadena de sentido negativo no segmentada
EP2712871A1 (en) * 2012-09-27 2014-04-02 Institut Pasteur Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications
WO2016199936A1 (ja) * 2015-06-12 2016-12-15 国立大学法人三重大学 ヒトパラインフルエンザ２型ウイルスベクター及びワクチン
WO2016210127A1 (en) * 2015-06-25 2016-12-29 Technovax, Inc. Flavivirus and alphavirus virus-like particles (vlps)
EP3184119A1 (en) * 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses

Also Published As

Publication number Publication date
US11857616B2 (en) 2024-01-02
WO2018224573A1 (en) 2018-12-13
EP3634482A1 (en) 2020-04-15
BR112019025310A2 (pt) 2020-06-23
AU2018281889B2 (en) 2022-03-03
CN110891600B (zh) 2024-04-02
EP3412307A1 (en) 2018-12-12
CA3064322A1 (en) 2018-12-13
US20200237893A1 (en) 2020-07-30
CN110891600A (zh) 2020-03-17
AU2018281889A1 (en) 2019-12-19
JP2020524496A (ja) 2020-08-20
JP2023107780A (ja) 2023-08-03
WO2018224573A8 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
MX2019014674A (es) Virus recombinante de sarampion que expresa proteinas de virus zika y sus aplicaciones.
PH12015500499A1 (en) Recombinant measles virus expressing chikungunya virus polypeptides and their applications
BR112018071584A2 (pt) métodos para modular de maneira seletiva a ativida-de de subtipos distintos de células
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
BR112018009032A8 (pt) vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, método para o tratamento ou a prevenção de infecção pelo vírus da hepatite b em um paciente, uso de um vetor viral, ácido nucleico isolado, vetor viral de arenavírus infeccioso deficiente em replicação e método para sua geração
PH12020500569A1 (en) Influenza virus vaccines and uses thereof
EA201990718A1 (ru) Векторы аденовируса собачьих
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
PH12017500450A1 (en) Flavivirus virus like particle
PH12016502554A1 (en) A dengue virus chimeric polyepitope composed of fragments of non structural proteins and its use in an immunogenic composition against dengue virus infection
HRP20240163T1 (hr) Metode i pripravci za izazivanje zaštitnog imuniteta protiv infekcije filovirusom
MX2020006476A (es) Vacuna contra el virus de lassa.
MX2022002766A (es) Vacunas contra el virus de la gripe y usos de las mismas.
MY189334A (en) Lentiviral vector-based japanese encephalitis immunogenic composition
WO2020035609A3 (en) Immunogenic compositions and uses thereof
MX2023000041A (es) Composiciones y metodos para inducir una respuesta inmunitaria contra coronavirus.
PH12020550569A1 (en) A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition
WO2018115509A3 (en) New flavivirus vaccine
MX2018000023A (es) Particulas semejantes a virus recombinantes que utilizan la proteina gag del virus de inmunodeficiencia bovina.
WO2012038832A3 (en) Generation of replicating chimeric measles virus - retrovirus particles
CL2023001846A1 (es) Parapoxvirus modificado que tiene inmunogenicidad incrementada
MX2017014417A (es) Vacunas contra el dengue.
WO2014151687A3 (en) Compositions and methods to treat aids
PE20221731A1 (es) NUEVO USO DE FORMULACION INMUNOGENICA BCG QUE EXPRESA UNA PROTEINA DE VIRUS RESPIRATORIO SINCICIAL CONTRA hMPV